Producer
Phyton Biotech LLC
American biotechnology company (Port Jervis, New York; Orange County; subsidiary of DFB Pharmaceuticals, a private pharmaceutical holding company); the world's largest producer of paclitaxel API by plant cell fermentation (PCF) technology, and the only major non-Chinese paclitaxel API manufacturer. Phyton grows Taxus (yew) plant cells in large-scale bioreactors rather than extracting from harvested yew bark or needles — a proprietary PCF platform that produces pharmaceutical-grade paclitaxel without any yew tree logging. The technology originated from research at Washington State University and was commercialized by DFB with FDA approval. Phyton's Port Jervis facility supplies paclitaxel API to Bristol-Myers Squibb (Taxol brand), Fresenius Kabi (generic oncology), and other pharmaceutical manufacturers. PCF eliminates the ecological and supply vulnerability of tree-harvest routes: a bioreactor can be scaled in months, while yew plantation maturation takes 10-20 years. Phyton represents the only significant production capacity for paclitaxel API located in the United States.
1
Inputs supplied
1
Goods downstream
1
Facilities
0
Stories
What they make
1 input Phyton Biotech LLC supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Phyton Biotech LLC makes, pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
Paclitaxel API (Plant Cell Fermentation)
80%Contract Fermentation Services
15%Research & Development
5%
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Did you know2023
Phyton Biotech's plant cell fermentation (PCF) technology platform — developed originally for paclitaxel API production — is a general-purpose biotechnology for producing any plant-derived secondary metabolite at commercial scale without growing whole plants. The same bioreactor infrastructure and cell culture expertise used to manufacture paclitaxel from Taxus plant cells can be applied to: (1) other pharmaceutical alkaloids (vincristine from Catharanthus; colchicine from Colchicum); (2) high-value flavor and fragrance compounds (vanillin from vanilla cells, saffron compounds from Crocus cells); (3) nutraceuticals and food ingredients (resveratrol from grape cells; lycopene from tomato cells); (4) cannabis-derived compounds at pharmaceutical-grade purity without agricultural cultivation. Phyton Biotech's Port Jervis plant is the only FDA-licensed commercial PCF pharmaceutical manufacturing facility in the United States. The technology is simultaneously a pharmaceutical production platform, a food ingredient manufacturing platform, a cosmetic ingredient platform, and a potential biosynthesis platform for controlled substances (the same cell culture technology that makes paclitaxel could theoretically make morphine-precursor alkaloids from Papaver cells). The US government has invested in PCF as a domestic pharmaceutical supply chain resilience measure; the same technology is relevant to biodefense pharmaceutical manufacturing for any botanical-derived medical countermeasure.
Phyton Biotech ↗Origin2023
Phyton Biotech's plant cell fermentation (PCF) technology was developed in the 1980s-90s to solve a conservation crisis: when paclitaxel (Taxol) was proven as a breakthrough cancer drug in 1992, the only known source was Pacific yew (Taxus brevifolia) bark — and estimates showed that treating all US breast and ovarian cancer patients would require stripping essentially the entire remaining Pacific yew forest. USDA and NIH funded research into alternative production methods; plant cell fermentation — growing yew callus cells in bioreactors to biosynthetically produce paclitaxel without harvesting trees — emerged as the solution. Phyton commercialized this technology in Port Jervis, New York, becoming the only significant non-Chinese paclitaxel manufacturer.
Phyton Biotech LLC ↗